Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355112 | 0.82 | HTR6 (0.60) | HTR6DRD2CA12CA1CA2 | |
| SCHEMBL3568121 | 0.78 | HTR6 (0.38) | HTR6MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL2111716 | 0.72 | HTR6 (0.42) | HTR6DRD2CA12CA1CA2 | |
| SCHEMBL1468084 | 0.70 | AKR1C3 (0.54) | HTR6KDM4EMEN1MAPTHPGD | |
| SCHEMBL13221493 | 0.70 | DPP4 (0.47) | APPKDM4EMEN1MAPTHPGD | |
| SCHEMBL5350245 | 0.69 | HTR6 (0.55) | HTR6DRD2CA12CA1CA2 | |
| SCHEMBL2137464 | 0.69 | KDM4E (0.64) | HTR6CA1CA2CA9KDM4E | |
| SCHEMBL5354623 | 0.67 | HTR6 (0.52) | HTR6DRD2CA12CA1CA2 | |
| SCHEMBL2557854 | 0.65 | APP (0.40) | APPHPGDDPP4CYP3A4 | |
| SCHEMBL4218405 | 0.64 | KDM4E (0.47) | HTR6APPCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| CN-100522161-C | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2009-08-05 | — | — | CN | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| CN-1929836-A | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725232-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005089754-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | AKZO NOBEL N.V. (NL) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | HTR6 56/4885APP 2614/4885DRD2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.